Endometrial Cancer News and Research

RSS

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Aeterna Zentaris Inc. today announced that a poster on its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131, was presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

6 Apr 2011

Metformin therapy may protect PCOS women against endometrial cancer

Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also in women with Polycystic vary syndrome, may potentially provide protection against endometrial cancer.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Vitamin D can reduce estrogen receptor-positive breast cancer

In mice models of breast cancer, researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, found that vitamin D significantly reduced development of estrogen receptor-positive breast cancer both in lean and obese mice, but had no beneficial effect in estrogen receptor-negative cancer.

5 Apr 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

'Fetus To Fifth Grade' book provides updated research on pregnancy and childcare

Recent scientific studies have brought into sharp focus the importance of, and exactly what type of, mother/child interaction leads to an optimal outcome for the child.

17 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Tamoxifen against breast cancer can save lives and reduce medical costs

Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

14 Mar 2011

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Aeterna Zentaris Inc. and Yakult Honsha Co., Ltd. today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan.

9 Mar 2011

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces its featured products at the European Society of Radiology's annual meeting being held in Vienna, Austria from March 3 - 7, 2011.

3 Mar 2011

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P..

28 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Women need good nutrition and regular exercise

Obesity levels are at an all-time high among men, women, and children in the United States. The need for good nutrition and regular exercise is paramount for maintaining proper health and for keeping those extra pounds at bay, especially for women.

11 Feb 2011

Robot-assisted surgery improves outcomes in uterine, endometrial, and cervical cancer patients

Robot-assisted surgery dramatically improves outcomes in patients with uterine, endometrial, and cervical cancer, said researchers at the Jewish General Hospital's Lady Davis Institute for Medical Research in Montreal. Moreover, because of fewer post-operative complications and shorter hospital stays, robotic procedures also cost less.

13 Jan 2011

New predictive medicine product for hereditary pancreatic and related cancers

Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.

21 Dec 2010

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aeterna Zentaris Inc. today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).

20 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.

9 Dec 2010

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.

7 Dec 2010

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Myriad Genetics, Inc. today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome called Lynch Syndrome, is both medically and cost effective.

30 Nov 2010

Endometrial Cancer News and Research

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Metformin therapy may protect PCOS women against endometrial cancer

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Vitamin D can reduce estrogen receptor-positive breast cancer

MnSOD oral drug can protect against lung cancer radiation therapy

'Fetus To Fifth Grade' book provides updated research on pregnancy and childcare

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Tamoxifen against breast cancer can save lives and reduce medical costs

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Women need good nutrition and regular exercise

Robot-assisted surgery improves outcomes in uterine, endometrial, and cervical cancer patients

New predictive medicine product for hereditary pancreatic and related cancers

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News